Onco360 ®, the nation’s leading independent specialty pharmacy, has been selected as a national pharmacy partner by Astellas for Vyloy ® (zolbetuximab-clzb), approved in combination with ...

Thanks to the recently published data, zolbetuximab has now been approved as a drug in Europe. Patients with gastric cancer are expected to be able to be treated with it in Germany from the end of ...

VYLOY is the first and only CLDN18.2-targeted treatment approved in the U.S. for adults with advanced gastric and gastroesophageal junction cancer whose tumors are CLDN18.2 positive In the ...

Thanks to the recently published data, zolbetuximab has now been approved as a drug in Europe. Patients with gastric cancer are expected to be able to be treated with it in Germany from the end of ...

The latest approval, zolbetuximab, puts them on path to have 3 blockbuster drugs in the market at the same time. Although priced for aggressive growth as of now, ALPMF has enough fuel to ...

10月18日，FDA宣布批准Claudin18.2单抗Vyloy（zolbetuximab）上市，将其作为肿瘤Claudin18.2阳性的局部晚期不可切除或转移性胃癌，以及HER2阴性胃食管交界处 ...

Credit: Astellas. Vyloy is a claudin 18.2-directed cytolytic antibody. In clinical trials, CLDN18.2 positivity was determined by immunohistochemistry on gastric or GEJ tumor tissue specimens with ...

Investigational Pipeline in CLDN18.2 A Phase 2 trial of zolbetuximab in metastatic pancreatic adenocarcinoma is in progress. The trial is a randomized, multi-center, open-label study, evaluating ...

Investigational Pipeline in CLDN18.2 A Phase 2 trial of zolbetuximab in metastatic pancreatic adenocarcinoma is in progress. The trial is a randomized, multi-center, open-label study, evaluating the ...